Clinical Trial Update: Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC [Phase 2]

View source ↗

Summary

A randomized Phase II trial comparing nivolumab plus ipilimumab to standard of care in untreated and advanced non-clear cell renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Goethe University | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: COMPLETED